The multicentre IVIST@-trial should prove that additional steering of immunosuppressive and antiviral therapy by Tvis levels leads to better graft function by avoidance of over-immunosuppression ( for example , viral infections ) and drug toxicity ( for example , nephrotoxicity ) .